CytoDyn Inc. (CYDY)
Market Closed
18 Dec, 20:00
OTCQB OTCQB Primary $
0. 28
-0.01
-3.45%
$
146.38M Market Cap
- P/E Ratio
0% Div Yield
1,493,600 Volume
- Eps
$ 0.29
Previous Close Day Range
0.28 0.32
Year Range
0.11 0.49
Want to track CYDY and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 40 days
Summary
CYDY closed today lower at $0.28, a decrease of 3.45% from yesterday's close, completing a monthly increase of 7.69% or $0.02. Over the past 12 months, CYDY stock gained 133.33%.
CYDY is not paying dividends to its shareholders.
The last earnings report, released on Oct 29, 2025, missed the consensus estimates by 0%. On average, the company has fell short of earnings expectations by 0%, based on the last three reports. The next scheduled earnings report is due on Jan 28, 2026.
The stock of the company had never split.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on OTCQB (USD).
CytoDyn Inc. (CYDY) FAQ
What is the stock price today?
The current price is $0.28.
On which exchange is it traded?
CytoDyn Inc. is listed on OTCQB.
What is its stock symbol?
The ticker symbol is CYDY.
Does it pay dividends? What is the current yield?
Yes, It pays dividends and the current yield is 0%.
What is its market cap?
As of today, the market cap is 146.38M.
When is the next earnings date?
The next earnings report will release on Jan 28, 2026.
Has CytoDyn Inc. ever had a stock split?
No, there has never been a stock split.
CytoDyn Inc. Profile
| Biotechnology Industry | Healthcare Sector | Dr. Jacob P. Lalezari M.D. CEO | OTCQB Exchange | US23283M1018 ISIN |
| United States Country | 9 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
CytoDyn Inc. is a clinical-stage biotechnology firm focusing on the development of treatments across multiple therapeutic indications. Originally known as RexRay Corporation, the company was rebranded to CytoDyn Inc. following its incorporation in 2002. Based in Vancouver, Washington, CytoDyn positions itself at the forefront of addressing critical health challenges, including COVID-19, HIV, metabolic dysfunction-associated steatohepatitis (MASH), and various forms of cancer, specifically targeting metastatic triple-negative breast cancer. Through dedicated research and development, CytoDyn aims to leverage cutting-edge biotechnological approaches to improve health outcomes for patients worldwide.
Products and Services
CytoDyn is involved in the clinical development of its flagship therapeutic candidate, leronlimab:
- Leronlimab (COVID-19): This novel humanized monoclonal antibody is aimed at combating the novel coronavirus by targeting the C-C chemokine receptor type 5 (CCR5). Its potential in COVID-19 treatment highlights CytoDyn's commitment to addressing global health emergencies.
- Leronlimab (HIV): Designed to target the CCR5 receptor, leronlimab is under development as a promising therapeutic option for patients suffering from human immunodeficiency virus (HIV) with the potential to improve patient outcomes significantly.
- Leronlimab (Metabolic Dysfunction-Associated Steatohepatitis - MASH): In the realm of metabolic disorders, leronlimab is in phase 2 development for treating NASH, a serious liver disease, showcasing CytoDyn's expansion into treatments for metabolic dysfunction.
- Leronlimab (Solid Tumors in Oncology): The company is exploring the efficacy of leronlimab in treating solid tumors, including metastatic triple-negative breast cancer. This involves investigating the antibody's impact on tumor growth and metastasis in the oncology sector.
- Leronlimab (HIV NASH): Beyond standard HIV treatment, leronlimab is being studied for its effectiveness in patients suffering from both HIV and NASH, exemplifying a multifaceted approach to complex co-morbidities.
- Leronlimab (HIV-PreP and HIV-Cure): CytoDyn is also advancing pre-clinical developments with leronlimab for both the prevention (PrEP) and the cure of HIV, underpinning a long-term vision toward eradicating the disease.
Contact Information
Address: 1111 Main Street
Phone: 360 980 8524
Website: https://www.cytodyn.com
